Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
Active, not recruiting · NCT01872260 · Registry updated 2026-09-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-18 | NCT01872260 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Novartis Pharmaceuticals | 432 |
10 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| H Lee Moffitt Cancer Center and Research Institute | Tampa | United States | 11 |
| Massachusetts General Hospital | Boston | United States | 1015 |
| Massachusetts General Hospital SC-5 | Boston | United States | 1 |
| Mays Cancer Ctr Uthsa Mdacc | San Antonio | United States | 2 |
| Northwest Medical Specialties | Tacoma | United States | 32 |
| Tennessee Oncology | Nashville | United States | 77 |
| Texas Oncology | Amarillo | United States | 3 |
| UCSF Medical Center | San Francisco | United States | 26 |
| Univ of California at San Diego Moores Cancer Ctr | San Diego | United States | 1 |
| Vanderbilt University Medical Ctr | Nashville | United States | 2 |